Pharma Business - March 29, 2016
AZ’s Tagrisso approved in Japan
The Japanese Ministry of Health, Labour and Welfare has approved Tagrisso (osimertinib, AZD9291) 80mg once-daily tablets for the treatment of patients with epidermal growth factor receptor (EGFR) T790M mutation-positive inoperable or recurrent non-small cell lung cancer (NSCLC) that is resistant to EGFR tyrosine kinase inhibitor (TKI) therapy. Sean Bohen, Executive Vice President, Global Medicines Development […]
Pharma Business - September 27, 2013
Medivir’s Simeprevir has been approved in Japan
Medivir today reports that that simeprevir has been approved for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. “The approval in Japan is a very important step in providing patients with new treatment options. It is the first approval based on the series of global filings that our partner initiated during 2013. […]
Pharma Business - September 23, 2013
Orexo announces the approval of Abstral in Japan
Orexo AB has announced the approval of Abstral (fentanyl) sublingual tablets in Japan. The product has been registered and will be sold by Kyowa Hakko Kirin Co., Ltd. Based on the agreement, the approval will trigger a milestone payment to Orexo. Kyowa Hakko Kirin and its subsidiaries have the rights for Abstral in all markets […]
